Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad-CCL21-DC Vaccine + Pembrolizumab in Advanced NSCLC
NCT03546361Phase 1Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jul 2019
- Primary completion
- Jan 2026
- Modality
- Gene Editing, Whole Cell Cancer Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CCL21 gene-modified dendritic cells in non-small cell lung cancer (NSCLC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose at 28 days and Overall Response Rate at 1 year. Started Jul 2019; status: active, not recruiting.
02
Drugs
CCL21 gene-modified dendritic cells
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03546361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03546361.